Chris Ryan

Patients with relapsed or refractory large B-cell lymphoma experienced better quality of life when they received second-line treatment with lisocabtagene maraleucel vs standard of care.

A single infusion of ciltacabtagene autoleucel produced early and deep responses and encouraging minimal residue disease negativity in patients with multiple myeloma who experienced early clinical relapse following initial therapy.

Ciltacabtagene autoleucel demonstrated a significant advantage over physician’s choice of treatment with regard to overall survival, progression-free survival, time to next treatment, and overall response rate, underscoring its potential for use in patients with triple-class relapsed/refractory multiple myeloma.

The addition of isatuximab to lenalidomide, bortezomib, and dexamethasone (RVd) demonstrated superior minimal residual disease rates vs RVd alone when used as induction treatment in patients with transplant-eligible newly diagnosed multiple myeloma.

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole resulted in prolonged central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer.

Datopotamab deruxtecan showed highly encouraging and durable efficacy through overall response rates in patients with advanced or metastatic triple-negative breast cancer.

Lisocabtagene maraleucel significantly prolonged event-free survival and progression-free survival and improved complete responses when used in the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.

AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.

The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival in patients with endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer. Though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease.

The administration of trilaciclib prior to chemotherapy reduced chemotherapy-induced myelosuppression and the need for associated supportive care in patients with extensive-stage small cell lung cancer.